FAQ
Common Questions on Retatrutide — Answered Directly
22 questions, direct answers, figures cited. No filler.
What is Retatrutide?
Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide developed by Eli Lilly. It is an investigational compound — not approved for prescription or use outside clinical trials anywhere in the world as of 2026. It functions as a triple agonist, activating three hormone receptors: GLP-1, GIP, and glucagon. In Phase 2 trials, it produced weight loss of up to -24.2% at 48 weeks [1].
What does retatrutide do?
Retatrutide activates three metabolic hormone receptors simultaneously — GLP-1, GIP, and glucagon. GLP-1 receptor activation suppresses appetite and improves glucose-dependent insulin secretion. GIP adds insulinotropic and adipose-tissue effects. Glucagon receptor activation increases energy expenditure and accelerates hepatic lipid metabolism. Together, the three-receptor approach produced the largest weight losses in a once-weekly injectable seen in Phase 2 controlled trials to date [1][6].
What is retatrutide used for?
In clinical trials, retatrutide is being studied for obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD — fatty liver), and related cardiovascular and kidney outcomes. It is not approved for any indication. It is not available as a treatment. Clinical trial information is available at ClinicalTrials.gov under the TRIUMPH and TRANSCEND program identifiers.
What is retatrutide made of?
Retatrutide is a synthetic single-molecule peptide — 39 amino acids in a chain built on a GIP-based backbone, modified with a C20 fatty diacid at a specific position to bind albumin in the bloodstream and extend the half-life to approximately 6 days. Molecular formula C221H342N46O68; molecular weight 4731.33 Da; CAS number 2381089-83-2. It does not occur naturally — it is an engineered molecule designed to mimic and enhance the metabolic actions of three endogenous hormones.
Is retatrutide a GLP-1 receptor agonist or something different?
It is more than a GLP-1 receptor agonist. Retatrutide is a triple agonist — it activates GLP-1, GIP, and glucagon receptors simultaneously in a single molecule. The 'GLP-3' label that circulates online is a misnomer: there is no GLP-3 receptor. Retatrutide belongs to the GIP/GLP-1/glucagon tri-agonist class. The glucagon component, absent from pure GLP-1 agents, is what drives the additional energy expenditure and hepatic lipid clearance seen in trials [3][6].
What is Retatrutide's approval status in the US?
Not approved. Retatrutide is an investigational drug in Phase 3 clinical trials as of 2026. No New Drug Application has been submitted to the FDA. It cannot be legally prescribed or dispensed in the United States. Eli Lilly is conducting the TRIUMPH and TRANSCEND Phase 3 programs, but no regulatory timeline for submission or approval has been publicly confirmed.
Is Retatrutide a natural hormone?
No. Retatrutide is a synthetic engineered peptide. It is designed to mimic and activate the receptors of three natural hormones — GLP-1, GIP, and glucagon — but it is not itself any of those hormones, and it does not occur naturally in the body. It was specifically engineered with a fatty-diacid modification to extend its half-life well beyond the minutes-long half-lives of the native hormones it mimics.
What to expect when taking Retatrutide?
This site describes research findings, not clinical advice. In trials, the most commonly documented effects at higher doses were: significant weight reduction over weeks to months, nausea especially early and at higher doses, a modest resting heart rate increase, and occasional diarrhea or constipation [1][2]. Community reports align with the GI profile but are anecdotal and unverified. Retatrutide is investigational; what any individual would experience is not knowable from trial averages alone.
What is retatrutide (GGG tri-agonist / LY3437943) and what is its potential for treating obesity and diabetes?
Retatrutide (also called LY3437943 or GGG tri-agonist, referring to the GIP/GLP-1/Glucagon triple agonism) is Eli Lilly's investigational triple-agonist peptide. In Phase 2, it reduced body weight by -24.2% over 48 weeks in obesity and lowered HbA1c by -2.02% in type 2 diabetes at the highest dose studied [1][2]. In Phase 3 T2D data, HbA1c fell by -1.94% and body weight by -15.3% [12]. If approved, it would represent a step-change in pharmacological weight management — pending Phase 3 completion and regulatory review.
What is retatrutide (LY3437943) and why is it being studied heavily?
Retatrutide is the subject of intense clinical development because Phase 2 data showed weight losses (-24.2%) that surpass prior approved GLP-1-class agents and approach bariatric surgery outcomes in a non-surgical weekly injection. The triple-agonist mechanism — simultaneously targeting GLP-1, GIP, and glucagon — distinguishes it structurally from approved dual-agonist compounds. A 2025 review described it as a potential game-changer in obesity pharmacotherapy [6], a characterization consistent with the Phase 2 size-of-effect data.
What is retatrutide's half-life and how long does it stay in the body?
Retatrutide's half-life is approximately 6 days, established in the Phase 1b first-in-human pharmacokinetics study [4]. This means blood levels fall by half every ~6 days after the last dose. The compound reaches pharmacokinetic steady state within about 4–5 weeks of weekly dosing. After discontinuation, meaningful concentrations persist for several weeks.
What is retatrutide's mechanism of action and how does activating three receptors differ from activating two?
Retatrutide's three-receptor strategy adds glucagon receptor agonism to the GIP/GLP-1 dual-agonist foundation. GLP-1 and GIP arms handle appetite suppression and glucose-dependent insulin secretion. The glucagon arm adds energy expenditure via thermogenic hepatic and metabolic pathways, and accelerates fat metabolism — effects absent from pure GLP-1 or dual GIP/GLP-1 agents. In the Phase 2 obesity trial, retatrutide 12 mg at 48 weeks produced -24.2% weight loss — greater than tirzepatide's Phase 3 peak, attributed in part to the additive glucagon contribution [1][6].
What is retatrutide's significance for conditions beyond obesity, such as sleep apnea or osteoarthritis?
Phase 2 data already show significant liver-fat reduction (-82.4% at 12 mg) in MASLD [5], and cardiovascular/kidney outcomes trials are ongoing. Sleep apnea is expected to benefit from weight reduction, consistent with class-level data for GLP-1 agents. Osteoarthritis relief associated with weight loss is plausible but not specifically studied for retatrutide. A 2026 review noted that retatrutide's multi-receptor approach positions it for broad clinical utility beyond glucose lowering — hepatic, cardiovascular, and inflammatory domains included [10].
Why is retatrutide being studied so heavily?
Three reasons: the Phase 2 weight loss data (-24.2% at 48 weeks) are unprecedented in the once-weekly injectable category [1]; the triple-agonist mechanism addresses appetite, glucose handling, and energy expenditure through separate complementary pathways rather than just amplifying a single signal; and the liver-fat data (-82.4% liver fat clearance in MASLD) [5] open therapeutic potential beyond pure weight loss into metabolic liver disease — a large unmet need with few approved options.
How does retatrutide work?
Retatrutide simultaneously activates three class-B G-protein-coupled receptors: GLP-1R, GIPR, and GCGR. GLP-1 receptor signaling suppresses appetite, slows gastric emptying, and drives glucose-dependent insulin secretion. GIP receptor signaling adds insulinotropic and adipose effects. Glucagon receptor signaling increases energy expenditure and accelerates hepatic lipid breakdown — driving calories burned upward while GLP-1 is driving intake down. The compound binds with differential potency: 8.9× at GIPR (superagonist relative to native GIP), 0.4× at GLP-1R, 0.3× at GCGR [3]. The structural details are on how does retatrutide work.
How to reconstitute retatrutide?
This site does not provide reconstitution instructions. In clinical trials, retatrutide was supplied as a formulated injectable by Eli Lilly — researchers did not reconstitute powder. No approved reconstitution standard exists. Gray-market preparations are unverified for identity and purity; providing preparation instructions for an unknown substance would not be responsible editorial practice. This compound belongs in a clinical setting with verified product and prescriber oversight — neither applies to research-labeled gray-market material.
Is retatrutide FDA approved?
No. Retatrutide is not approved by the FDA or any regulator as of mid-2026. It is in Phase 3 trials. The first Phase 3 readout (TRANSCEND-T2D-1) was published in 2026 and confirmed Phase 2 efficacy at Phase 3 scale [12], but regulatory submission requires all Phase 3 trials to complete and data packages to be reviewed — a process that has not yet occurred.
When will retatrutide be available?
No confirmed date. Phase 3 trials are ongoing. TRIUMPH-1 (obesity), TRIUMPH-2, and multiple outcome trials (cardiovascular, kidney, active comparator) are still running. A regulatory submission would follow completion and data analysis of the full Phase 3 program. Public timelines attributed to Eli Lilly represent investor communications subject to change; this site will not project approval dates from those statements.
How to take retatrutide?
In trials, retatrutide was administered by subcutaneous injection (under the skin) once weekly. This site does not advise on self-administration. The compound is investigational and unaccepted for human use outside clinical trials. All dosing in trials was conducted under clinical supervision with stepwise escalation schedules and regular monitoring for GI, cardiovascular, and metabolic adverse events [1][2]. None of that monitoring applies to uncontrolled research-labeled use.
How long does retatrutide take to work?
In Phase 2 obesity trials, weight loss began to separate from placebo within the first 4–8 weeks and continued accumulating through week 48 [1]. The peak mean weight loss of -24.2% at 12 mg was measured at 48 weeks. Blood-sugar improvement in type 2 diabetes was detectable at the 12-week assessment in Phase 1b [4]. The compound reaches pharmacokinetic steady state in approximately 4–5 weeks due to its ~6-day half-life.
Is retatrutide better than tirzepatide?
Cross-trial comparison suggests larger weight loss in Phase 2 retatrutide data (-24.2% at 48 weeks) versus tirzepatide Phase 3 data (~20–22% at comparable durations). A 2026 review confirmed that retatrutide achieves weight reduction currently unmatched in the oral/injectable pipeline [14]. However, no randomized head-to-head trial has reported. The TRIUMPH program includes an active-comparator arm versus tirzepatide; until that reports, cross-trial comparisons are informative but not definitive. On class-level limitations — weight regain after discontinuation — both agents appear subject to the same pattern [14].
How much retatrutide per week?
In the Phase 2 obesity trial, doses studied were 1, 4, 8, and 12 mg once weekly subcutaneous injection [1]. In the Phase 2 diabetes trial, doses ranged from 0.5 mg to 12 mg with stepwise escalation [2]. These are study-design facts, not dosing instructions. Retatrutide is not approved; no human dose is recommended here or elsewhere outside of clinical-trial protocols.
Retatrutide cost
Retatrutide has no approved retail price — it is investigational and not commercially available. Gray-market research-labeled material carries prices that vary widely by vendor and formulation, but those products are unverified, unregulated, and potentially mislabeled. If and when retatrutide receives regulatory approval, pricing will depend on the indication, reimbursement negotiations, and market dynamics at the time of launch — none of which are established.